{"id":"php-201-ophthalmic-solution","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details for PHP-201 are limited in public literature, ophthalmic solutions in phase 3 development typically work by reducing ocular surface inflammation, enhancing tear film stability, or promoting corneal epithelial healing. The exact molecular target and mechanism for PHP-201 require access to clinical trial protocols or company disclosures.","oneSentence":"PHP-201 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:51:13.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ocular surface disease (presumed, based on formulation type)"}]},"trialDetails":[{"nctId":"NCT04863365","phase":"PHASE3","title":"A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"UNKNOWN","sponsor":"pH Pharma","startDate":"2021-11","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":110},{"nctId":"NCT03106532","phase":"PHASE2","title":"Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma","status":"COMPLETED","sponsor":"pH Pharma","startDate":"2017-03-06","conditions":"Normal Tension Glaucoma","enrollment":119},{"nctId":"NCT03586908","phase":"PHASE1","title":"PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy Subjects","status":"COMPLETED","sponsor":"pH Pharma","startDate":"2018-02-04","conditions":"Healthy Volunteer","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sovesudil"],"phase":"phase_3","status":"active","brandName":"PHP-201 ophthalmic solution","genericName":"PHP-201 ophthalmic solution","companyName":"pH Pharma","companyId":"ph-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PHP-201 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms. Used for Ocular surface disease (presumed, based on formulation type).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}